HANDOK Past Earnings Performance

Past criteria checks 0/6

HANDOK's earnings have been declining at an average annual rate of -38.1%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 4% per year.

Key information

-38.1%

Earnings growth rate

-38.5%

EPS growth rate

Pharmaceuticals Industry Growth	11.3%
Revenue growth rate	4.0%
Return on equity	-8.5%
Net Margin	-5.5%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

HANDOK Inc. (KRX:002390) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Jan 31

We're Not So Sure You Should Rely on HANDOK's (KRX:002390) Statutory Earnings

Jan 18

Here's Why I Think HANDOK (KRX:002390) Might Deserve Your Attention Today

Jan 05

Should HANDOK Inc. (KRX:002390) Be Part Of Your Dividend Portfolio?

Dec 23

What Kind Of Investors Own Most Of HANDOK Inc. (KRX:002390)?

Dec 10

HANDOK (KRX:002390) Has A Somewhat Strained Balance Sheet

Nov 27

Revenue & Expenses Breakdown
Beta

How HANDOK makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A002390 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	522,741	-28,797	114,448	28,672
30 Sep 23	532,175	-5,603	112,641	28,183
30 Jun 23	553,520	1,465	112,488	28,233
31 Mar 23	545,048	5,990	110,128	25,038
31 Dec 22	543,759	10,684	110,821	23,995
30 Sep 22	547,544	3,340	110,837	23,304
30 Jun 22	533,912	-2,796	108,836	23,553
31 Mar 22	525,677	1,736	107,867	23,176
31 Dec 21	517,641	3,295	105,644	22,879
30 Sep 21	509,684	15,001	109,206	23,203
30 Jun 21	507,947	31,457	108,713	22,044
31 Mar 21	506,784	29,556	109,243	21,105
31 Dec 20	503,612	26,960	108,816	20,135
30 Sep 20	500,639	31,426	107,475	18,168
30 Jun 20	486,597	33,993	107,724	18,028
31 Mar 20	478,080	27,508	106,772	19,062
31 Dec 19	473,000	34,929	107,711	19,240
30 Sep 19	460,805	16,348	107,074	20,611
30 Jun 19	457,578	3,897	104,680	20,193
31 Mar 19	453,718	9,409	105,369	20,197
31 Dec 18	446,731	7,990	104,571	21,119
30 Sep 18	423,154	15,959	100,464	21,634
30 Jun 18	420,585	15,988	102,710	23,209
31 Mar 18	416,710	13,192	102,953	23,029
31 Dec 17	417,970	4,869	102,565	22,449
30 Sep 17	427,730	-2,716	102,456	21,564
30 Jun 17	414,775	-8,991	101,068	19,977
31 Mar 17	409,977	-9,747	98,483	19,674
31 Dec 16	396,134	-6,454	97,745	18,472
30 Sep 16	392,841	1,726	97,543	17,730
30 Jun 16	383,877	1,316	95,500	18,386
31 Mar 16	365,587	2,406	92,229	17,171
31 Dec 15	358,448	-1,687	87,809	18,809
31 Dec 14	348,311	1,473	81,808	15,629
31 Dec 13	327,936	12,310	69,571	17,532
30 Sep 13	313,412	836	72,359	17,309
30 Jun 13	313,106	2,704	73,579	15,993

Quality Earnings: A002390 is currently unprofitable.

Growing Profit Margin: A002390 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A002390 is unprofitable, and losses have increased over the past 5 years at a rate of 38.1% per year.

Accelerating Growth: Unable to compare A002390's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A002390 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.1%).

Return on Equity

High ROE: A002390 has a negative Return on Equity (-8.5%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

HANDOK Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings released: ₩2,091 loss per share (vs ₩776 profit in FY 2022)

Third quarter 2023 earnings released: ₩223 loss per share (vs ₩290 profit in 3Q 2022)

First quarter 2023 earnings released: ₩316 loss per share (vs ₩25.00 profit in 1Q 2022)

Full year 2022 earnings released: EPS: ₩776 (vs ₩239 in FY 2021)

First quarter 2022 earnings released: EPS: ₩25.00 (vs ₩138 in 1Q 2021)

Third quarter 2021 earnings released: ₩155 loss per share (vs ₩1,040 profit in 3Q 2020)

Recent updates

Full year 2023 earnings released: ₩2,091 loss per share (vs ₩776 profit in FY 2022)

Upcoming dividend of ₩400 per share at 3.0% yield

Third quarter 2023 earnings released: ₩223 loss per share (vs ₩290 profit in 3Q 2022)

First quarter 2023 earnings released: ₩316 loss per share (vs ₩25.00 profit in 1Q 2022)

Full year 2022 earnings released: EPS: ₩776 (vs ₩239 in FY 2021)

Upcoming dividend of ₩350 per share

No independent directors

First quarter 2022 earnings released: EPS: ₩25.00 (vs ₩138 in 1Q 2021)

No independent directors

Upcoming dividend of ₩300 per share

Third quarter 2021 earnings released: ₩155 loss per share (vs ₩1,040 profit in 3Q 2020)

First quarter 2021 earnings released: EPS ₩138 (vs ₩50.00 loss in 1Q 2020)

Is HANDOK Inc.'s (KRX:002390) 1.0% Dividend Worth Your Time?

Full year 2020 earnings released: EPS ₩1,958 (vs ₩2,544 in FY 2019)

How Much Of HANDOK Inc. (KRX:002390) Do Insiders Own?

HANDOK (KRX:002390) Has A Somewhat Strained Balance Sheet

New 90-day low: ₩27,900

Did You Miss HANDOK's (KRX:002390) 21% Share Price Gain?

HANDOK Inc., Annual General Meeting, Mar 26, 2021

HANDOK Inc. to Report Fiscal Year 2020 Results on Feb 10, 2021

HANDOK Inc. (KRX:002390) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

New 90-day low: ₩29,550

We're Not So Sure You Should Rely on HANDOK's (KRX:002390) Statutory Earnings

Here's Why I Think HANDOK (KRX:002390) Might Deserve Your Attention Today

Should HANDOK Inc. (KRX:002390) Be Part Of Your Dividend Portfolio?

New 90-day high: ₩35,400

What Kind Of Investors Own Most Of HANDOK Inc. (KRX:002390)?

HANDOK (KRX:002390) Has A Somewhat Strained Balance Sheet

New 90-day low: ₩29,300

First half earnings released

New 90-day high - ₩36,550

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta